Marshall Wace LLP Makes New $432,000 Investment in Cabot Co. (NYSE:CBT)

Marshall Wace LLP purchased a new position in Cabot Co. (NYSE:CBT - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,698 shares of the specialty chemicals company's stock, valued at approximately $432,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in CBT. Assenagon Asset Management S.A. lifted its holdings in shares of Cabot by 571.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 127,116 shares of the specialty chemicals company's stock valued at $11,681,000 after buying an additional 108,197 shares during the period. Capital Research Global Investors lifted its holdings in shares of Cabot by 22.9% during the 1st quarter. Capital Research Global Investors now owns 521,486 shares of the specialty chemicals company's stock valued at $48,081,000 after buying an additional 97,101 shares during the period. Eventide Asset Management LLC bought a new position in shares of Cabot during the 4th quarter valued at $6,919,000. American Century Companies Inc. lifted its holdings in shares of Cabot by 7.3% during the 2nd quarter. American Century Companies Inc. now owns 976,709 shares of the specialty chemicals company's stock valued at $89,750,000 after buying an additional 66,171 shares during the period. Finally, Sei Investments Co. raised its holdings in Cabot by 5.9% in the 2nd quarter. Sei Investments Co. now owns 913,259 shares of the specialty chemicals company's stock worth $83,919,000 after purchasing an additional 51,178 shares during the period. Hedge funds and other institutional investors own 93.18% of the company's stock.

Cabot Price Performance

CBT stock traded up $0.40 during trading on Friday, reaching $111.17. The company's stock had a trading volume of 2,437 shares, compared to its average volume of 335,172. Cabot Co. has a 1 year low of $65.10 and a 1 year high of $113.12. The company has a quick ratio of 1.45, a current ratio of 2.22 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $6.09 billion, a P/E ratio of 13.18, a price-to-earnings-growth ratio of 0.93 and a beta of 1.19. The company's fifty day moving average is $103.67 and its 200-day moving average is $98.71.

Cabot (NYSE:CBT - Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The specialty chemicals company reported $1.92 earnings per share for the quarter, beating analysts' consensus estimates of $1.72 by $0.20. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Cabot had a return on equity of 26.99% and a net margin of 12.05%. The business's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.42 earnings per share. On average, research analysts expect that Cabot Co. will post 7.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on CBT shares. JPMorgan Chase & Co. raised their target price on Cabot from $95.00 to $105.00 and gave the stock a "neutral" rating in a report on Wednesday, August 7th. StockNews.com cut Cabot from a "strong-buy" rating to a "buy" rating in a report on Monday, June 24th. Finally, UBS Group decreased their target price on Cabot from $103.00 to $98.00 and set a "neutral" rating on the stock in a report on Tuesday, August 6th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, Cabot has an average rating of "Hold" and a consensus target price of $101.75.

Insider Activity

In related news, CEO Sean D. Keohane sold 25,617 shares of Cabot stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $101.55, for a total value of $2,601,406.35. Following the completion of the transaction, the chief executive officer now owns 331,174 shares in the company, valued at approximately $33,630,719.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO Sean D. Keohane sold 25,617 shares of Cabot stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $101.55, for a total value of $2,601,406.35. Following the completion of the transaction, the chief executive officer now owns 331,174 shares in the company, valued at approximately $33,630,719.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Erica Mclaughlin sold 23,274 shares of Cabot stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $99.79, for a total value of $2,322,512.46. Following the completion of the transaction, the chief financial officer now owns 59,814 shares of the company's stock, valued at approximately $5,968,839.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,939 shares of company stock worth $7,308,812 over the last 90 days. Corporate insiders own 3.07% of the company's stock.

About Cabot

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.